494 related articles for article (PubMed ID: 21295192)
21. Of fads, fashion, surrogate endpoints and dual RAS blockade.
Messerli FH; Staessen JA; Zannad F
Eur Heart J; 2010 Sep; 31(18):2205-8. PubMed ID: 20685681
[TBL] [Abstract][Full Text] [Related]
22. [Hypertension combination therapy with renin-angiotensin system blockers].
Soucek M
Vnitr Lek; 2009 Sep; 55(9):719-23. PubMed ID: 19785368
[TBL] [Abstract][Full Text] [Related]
23. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
[TBL] [Abstract][Full Text] [Related]
24. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension.
Gojanovic B; Feihl F; Liaudet L; Waeber B
J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):1-9. PubMed ID: 18404602
[TBL] [Abstract][Full Text] [Related]
25. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
Kushiro T; Itakura H; Abo Y; Gotou H; Terao S; Keefe DL
Hypertens Res; 2009 Mar; 32(3):169-75. PubMed ID: 19262478
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
27. ALTITUDE trial and dual RAS blockade: the alluring but soft science of the surrogate end point.
Messerli FH; Bangalore S
Am J Med; 2013 Mar; 126(3):e1-3. PubMed ID: 23332648
[No Abstract] [Full Text] [Related]
28. First orally active DRI Aliskiren--a new prospect in management of hypertension and beyond.
Sawhney JP
Indian Heart J; 2010; 62(1):49-56. PubMed ID: 21180035
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension.
Strasser RH; Puig JG; Farsang C; Croket M; Li J; van Ingen H
J Hum Hypertens; 2007 Oct; 21(10):780-7. PubMed ID: 17541390
[TBL] [Abstract][Full Text] [Related]
30. Direct renin inhibition with aliskiren in hypertension and target organ damage.
Müller DN; Luft FC
Clin J Am Soc Nephrol; 2006 Mar; 1(2):221-8. PubMed ID: 17699210
[TBL] [Abstract][Full Text] [Related]
31. [Renin as a target of direct pharmacological block in arterial hypertension].
Mukhin NA; Fomin VV
Ter Arkh; 2009; 81(8):5-9. PubMed ID: 19799192
[TBL] [Abstract][Full Text] [Related]
32. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
33. Managing peripheral edema in patients with arterial hypertension.
Epstein BJ; Roberts ME
Am J Ther; 2009; 16(6):543-53. PubMed ID: 19636244
[TBL] [Abstract][Full Text] [Related]
34. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
35. [Renin inhibition and the kidney].
Ecder T
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
[TBL] [Abstract][Full Text] [Related]
36. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
Weber MA; Giles TD
Rev Cardiovasc Med; 2006; 7(2):45-54. PubMed ID: 16915123
[TBL] [Abstract][Full Text] [Related]
37. Do we need yet another blocker of the renin-angiotensin system?
Messerli FH; Re RN
J Am Coll Cardiol; 2007 Mar; 49(11):1164-5. PubMed ID: 17367659
[No Abstract] [Full Text] [Related]
38. In brief: aliskiren trial terminated.
Med Lett Drugs Ther; 2012 Jan; 54(1382):5. PubMed ID: 22267213
[No Abstract] [Full Text] [Related]
39. Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients.
López V; Martin M; Cobelo C; Aranda P; Cabello M; Sola E; Gutierrez C; Burgos D; Martínez D; Hernandez D
Transplant Proc; 2010 Oct; 42(8):2883-5. PubMed ID: 20970559
[TBL] [Abstract][Full Text] [Related]
40. Therapy with renin-angiotensin system blockers after pulmonary vein isolation in patients with atrial fibrillation: who is a responder?
Berkowitsch A; Neumann T; Kuniss M; Janin S; Wojcik M; Zaltsberg S; Mitrovic V; Pitschner HF
Pacing Clin Electrophysiol; 2010 Sep; 33(9):1101-11. PubMed ID: 20487340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
